Intellia Therapeutics (NTLA) saw its shares climb sharply in after-hours trading Friday, gaining 19.3% to $16.26, ahead of the release of pivotal Phase 3 data from its HAELO study. The stock had closed the regular session at $13.63, down 14.1% on the day, but the pre-announcement optimism reversed the decline. The company is scheduled to present top-line results on Monday, April 27, at 8:00 a.m. EDT.
First Phase 3 Readout for In Vivo CRISPR
The HAELO trial evaluates lonvoguran ziclumeran (lonvo-z), a one-time infusion therapy designed to treat hereditary angioedema (HAE) by directly editing genes inside the body. This marks the first-ever Phase 3 data release for an in vivo CRISPR gene-editing treatment, a significant milestone for Intellia and the broader gene-editing field. The randomized, double-blind, placebo-controlled study enrolled 80 patients with Type I or Type II HAE, who received either a single 50 mg dose of lonvo-z or a placebo. The primary endpoint measures the number of HAE attacks from week 5 through week 28.
High Stakes for Intellia and Gene Editing
Success in this trial could pave the way for a biologics license application (BLA) in the second half of 2026, with a potential U.S. launch in the first half of 2027. The therapy targets the KLKB1 gene in the liver, reducing kallikrein production, a key driver of swelling episodes. Previous Phase 1/2 data showed that 31 of 32 patients on the 50 mg dose remained attack-free and required no ongoing prophylaxis at the data cutoff, with a favorable safety profile and follow-up extending to three years.
Competitive Landscape
The HAE market is becoming increasingly crowded. Ionis Pharmaceuticals received U.S. approval in 2025 for Dawnzera, a preventive therapy administered every four to eight weeks. Takeda’s Takhzyro remains a standard prophylactic, and KalVista’s Ekterly recently became the first oral on-demand treatment for acute HAE attacks to gain FDA clearance. Intellia aims to differentiate lonvo-z as a one-and-done curative option that could free patients from both attacks and chronic treatment.
Financial Runway
Intellia ended 2025 with $605.1 million in cash, cash equivalents, and marketable securities. Management expects this to fund operations into the second half of 2027, providing sufficient capital to support the planned U.S. launch of lonvo-z for HAE. However, the company has cautioned that early clinical results do not guarantee later success, and safety or durability concerns could delay regulatory timelines.
Risks and Setbacks
The path forward is not without risks. Intellia’s separate nex-z program for transthyretin amyloidosis was placed on clinical hold by the FDA after a patient in a heart-disease trial suffered severe liver issues and died. The hold was lifted only after regulators approved new trial safeguards. Investors will closely watch Monday’s webcast for attack-rate reductions, the proportion of patients remaining attack-free, and any liver-safety signals, as well as confirmation that the BLA timeline remains on track.
CEO John Leonard called 2026 a “pivotal” year for the company, emphasizing the importance of the HAELO data and the planned BLA submission. The outcome could either validate the promise of in vivo gene editing or introduce new uncertainties for the entire field.
